Farnesyltransferase inhibitors as radiation sensitizers

References

• ADER, I., MULLER, C., BONNET, J., FAVRE, G., COHENJONATHAN, E., SALLES, B. and TOULAS, C., 2002, The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene, 21, 6471–6479.
   PubMed Web of Science ®Google Scholar
• BARRINGTON, R. E., SUBLER, M. A., Rs, E., OMER, C. A., MILLER, P. J., HUNDLEY, J. E., KOESTER, S. K., TROYER, D. A., BEARSS, D. J., CONNER, M. W., GIBBS, J. B., HAMILTON, K., KOBLAN, K. S., MOSSER, S. D., O'NETT T T. J., SCHABER, M. D., SENDERAK, E. T., WINDLE, J. J., Onw, A. and Kont, N. E. A., 1998, Farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Molecular and Cellular Biology, 18, 85–92.
   Google Scholar
• BERNHARD, E. J., McKENNA, W. G., HAMILTON, A. D., SEBTI, S. M., QTAN, Y., Wu, J. M. and MUSCHEL, R. J., 1998, Inhibiting Ras prenylation increases the racliosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Research, 58, 1754–1761.
   PubMed Web of Science ®Google Scholar
• BERNHARD, E. J., STANBRIDGE, E. J., GuPTA, S., GuPTA, A. K., SOTO, D., BAKANAUSKAS, V. J., CERNIGLIA, G. J., MUSCHEL, R. J. and McKENNA, W. G., 2000, Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Research, 60, 6597–6600.
   PubMed Web of Science ®Google Scholar
• BUSER, C. A., DINSMORE, C. J., FERNANDES, C., GREENBERG, I., HAMILTON, K., MOSSER, S. D., WALSH, E. S., WILLIAMS, T. M. and KOBLAN, K. S., 2001, High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltrans-ferase inhibitor L-778,123. Analytical Biochemistry, 290, 126–137.
   PubMed Web of Science ®Google Scholar
• Buss, J. E., SOLSKI, P. A., SCHAEFFER, J. P., MACDONALD, M. J. and DER, C. J., 1989, Activation of the cellular proto-oncogene product p21 ras by addition of a myristylation signal. Science, 243, 1600–1602.
   PubMed Web of Science ®Google Scholar
• COHENJONATHAN, E., EVANS, S. M., KOCH, C. J., MUSCHEL, R. J., McKENNA, W. G., Wu, J. and BERNHARD, E. J., 2001, The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Research, 61, 2289–2293.
   PubMed Web of Science ®Google Scholar
• COHENJONATHAN, E., MUSCHEL, R. J., MCKENNA, W. G., EVANS, S. M., CERNIGLIA, G., MICK, R., KUSEWITT, D., SEBTI, S. M., HAMILTON, A. D., Onw, A., Kont, N., Gums," B. and BERNHARD, E. J., 2000, Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research, 154, 125–132.
   Google Scholar
• Cox, A. D. and DER, C. J., 1997, Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochimica et Biophysica Acta, 1333, F51–71.
   PubMed Web of Science ®Google Scholar
• ELTON, E. A., 1998, Routing MAP kinase cascades. Science, 281, 1625–1626.
   PubMed Web of Science ®Google Scholar
• END, D. W., SMETS, G., TODD, A. V., APPLEGATE, T. L., FUERY, C. J., ANGLBAUD, P., VENET, M., SANZ, G., POIGNET, H., SKRZAT, S., DEVINE, A., WOUTERS, W. and BOWDEN, C., 2001, Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Research, 61, 131–137.
   PubMed Web of Science ®Google Scholar
• END, D., SKRZAT, S. and DEVINE, A., 1998, R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems. Proceedings of the American Association of Cancer Research, 39, 270.
   Google Scholar
• EVANS, S. M., JOINER, B., JENKINS, W. T., LAUGHLIN, K. M., LORD, E. M. and KOCH, C. J., 1995, Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imiclazol-1-y1)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. British Journal of Cancer, 72, 875–882.
   PubMed Web of Science ®Google Scholar
• FENTON, B. M., PAONI, S. F., LEE, J., KOCH, C. J. and LORD, E. M., 1999, Quantification of tumour vasculature and hypoxia by immunohistochemical staining and Hb02 saturation measurements. British Journal of Cancer, 79, 464–471.
   PubMed Web of Science ®Google Scholar
• FITZGERALD, T. J., DAUGHERTY, C., KASE, K., ROTHSTEIN, L. A., McKENNA, M. and GREENBERGER, J. S., 1985, Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Implications for increased therapeutic ratio of low dose rate irradiation. American Journal of Clinical Oncology, 8, 517–522.
   PubMed Web of Science ®Google Scholar
• GLOMSET, J. A. and FARNSWORTH, C. C., 1994, Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annual Review of Cell Biology, 10, 181–205.
   PubMedGoogle Scholar
• GUPTA, A. K., BERNHARD, E. J., BAKANAUSKAS, V. J., Wu, J., MUSCHEL, R. J. and MCKENNA, W. G., 2000, RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiation Research, 154, 64–72.
   PubMed Web of Science ®Google Scholar
• GUPTA, A. K., BAKANAUSKAS, V. J., CERNIGLIA, G. J., CHENG, Y., BERNHARD, E. J., MUSCHEL, R. J. and MCKENNA, W. G., 2001, The Ras radiation resistance pathway. Cancer Research, 61, 4278–4282.
   PubMed Web of Science ®Google Scholar
• GUPTA, A. K., MCKENNA, W. G., WEBER, C. N., FELDMAN, M. D., GOLDSMITH, J. D., MICK, R., MACHTAY, M., ROSENTHAL, D. I., BAKANAUSKAS, V. J., CERNIGLIA, G. J., BERNHARD, E. J., WEBER, R. S. and MUSCHEL, R. J., 2002, Local recurrence in head and neck cancer: relationship to radiation resis-tance and signal transduction. Clinical Cancer Research, 8, 885–892.
   PubMed Web of Science ®Google Scholar
• HAGAN, M., WANG, L., HANLEY, J. R., PARK, J. S. and DENT, P., 2000, Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiation Research, 153, 371–383.
   PubMed Web of Science ®Google Scholar
• HAGEMANN, C. and BLANK, J. L., 2001, The ups and downs of MEK kinase interactions. Cell Signaling, 13, 863–875.
   PubMed Web of Science ®Google Scholar
• HAHN, S. M., BERNHARD, E. J., REGINE, W., MOHIUDDIN, M., HALLER, D. G., STEVENSON, J. P., Swim, D., PRAMANIK, B., TEPPER, J., DELANEY, T. F., KIEL, K. D., MORRISON, B., DEUTSCH, P., MUSCHEL, R. J. and MCKENNA, W. G., 2002, A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clinical Cancer Research, 8, 1065–1072.
   PubMed Web of Science ®Google Scholar
• HANCOCK, J. F., CADWALLADER, K. and MARSHALL, C. J., 1991, Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO Journal, 10, 641–646.
   PubMed Web of Science ®Google Scholar
• HANCOCK, J. F., MAGEE, A. I., CHILDS, J. E. and MARSHALL, C. J., 1989, All ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167–1177.
   PubMed Web of Science ®Google Scholar
• HANCOCK, J. F., PATERSON, H. and MARSHALL, C. J., 1990, A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21 ras to the plasma membrane. Cell, 63, 133–139.
   PubMed Web of Science ®Google Scholar
• HERMENS, A. F. and BENTVELZEN, P. A., 1992, Influence of the H-ras oncogene on radiation responses of a rat rhabdo-myosarcoma cell line. Cancer Research, 52, 3073–3082.
   PubMed Web of Science ®Google Scholar
• JACKSON, J., CocKRAN, C., BOURNE, J., SoLsm, P., Buss, J. and DER, C., 1990, Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proceedings of the National Academy of Sciences, USA, 87, 3042–3046.
   PubMed Web of Science ®Google Scholar
• KAS1D, U., PFEIFER, A., BRENNAN, T., BECKETT, M., WEICHSELBAUM, R. R., DRuscurto, A. and MARK, G. E., 1989, Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243, 1354–1356.
   PubMed Web of Science ®Google Scholar
• KOHL, N., OMER, C., CONNER, M., ANTHONY, N., DAVIDE, J., DESOLMS, S., GuiLLAATI, E., GOMEZ, R., GRAHAM, S., HAMILTON, K., HANDT, L., HARTMAN, G., KOBLAN, K.,
   Google Scholar
• KRAL, K., MILLER, P., MOSSER, S., N " --:—E1LL, T., RANDS, E., SCHABER, M., GIBBS, J. and OLIFF, A., 1995, Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine, 1, 792–797.
   Google Scholar
• Liu, U., CERNIGLIA, G. J., BERNHARD, E. J. and PRENDERGAST, G. C., 2001, RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proceedings of the National Academy of Sciences, USA, 98, 6192–6197.
   PubMed Web of Science ®Google Scholar
• LOBELL, R. B., OmER, C. A., ABRAMS, M. T., BHIMNATHWALA, H. G., BRUCKER, M. J., BUSER, C. A., DAVIDE, J. P., DESOLMS, S. J., DINSMORE, C. J., ELLIS-HUTCHINGS, M. S., KRAL, A. M., Liu, D., LummA, W. C., MACHOTKA, S. V., RANDS, E., WILLIANS, T. M., GGRAHAM, S. L., HARTMAN, G. D., OLIFF, A. I., HEMBROOK, D. C. and Kont, N. E., 2001, Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Research, 61, 8758–8768.
   Google Scholar
• MANGUES, R., CORRAL, T., Korm, N. E., SYM MANS, W. F., Lu, S., MALUMBRES, M., GIBBS, J. B., OLIFF, A. and PELLICER, A., 1998, Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overex-pressing N-ras in transgenic mice. Cancer Research, 58, 1253–1259.
   PubMed Web of Science ®Google Scholar
• MCKENNA, W. G., BERNHARD, E. J., MARKTEWICZ, D. A., RUDOLTZ, M. S., MArrst, A. and MUSCHEL, R. J., 1996, Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. Oncogene, 12, 237–245.
   PubMed Web of Science ®Google Scholar
• MCKENNA, W. G., WEISS, M. C., BAKANAUSKAS, V. J., SANDLER, H., KELSTEN, M. L., BIAGLOW, J., TUTTLE, S. W., ENDLICH, B., LING, C. C. and MUSCHEL, R. J., 1990a, The role of the H-ras oncogene in radiation resistance and metastasis. International Journal of Radiation Oncology Biology Physics, 18, 849–859.
   PubMed Web of Science ®Google Scholar
• MCKENNA, W. G., WEISS, M. C., ENDLICH, B., LING, C. C., BAKANAUSKAS, V. J., KELSTEN, M. L. and MUSCHEL, R. J., 1990b, Synergistic effect of the v-myc oncogene with H-ras on raclioresistance. Cancer Research, 50, 97–102.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN, J. and BASELGA, J., 2000, The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550–6565.
   PubMed Web of Science ®Google Scholar
• MYERS, M. P., PASS, I., BATTY, I. H., VAN DER KAAY, J., STOLAROV, J. P., HEMMINGS, B. A., WIGLER, M. H., DOWNES, C. P. and TONKS, N. K., 1998, The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proceedings of the National Academy of Sciences, USA, 95, 13513–13518.
   PubMed Web of Science ®Google Scholar
• NICHOLSON, K. M. and ANDERSON, N. G., 2002, The protein kinase B/Akt signalling pathway in human malignancy. Cell Signaling, 14, 381–395.
   PubMed Web of Science ®Google Scholar
• OmER, C. A., CHEN, Z., DIEHL, R. E., CONNER, M. W., CHEN, H. Y., TRUMBAUER, M. E., GOPAL-TRUTER, S., SEEBURGER, G., BITIMNATHWALA, H., ABRAMS, M. T., DAVIDE, J. P., ELLIS, M. S., GIBBS, J. B., GREENBERG, I., KOBLAN, K. S., KRAL, A. M., Liu, D., LOBETI, R. B., MILLER, P. J., MOSSER, S. D., O'NEILL, T. J., RANDS, E., SCHABER, M. D., SENDERAK, E. T., OLLFE, A. and Kont, N. E., 2000, Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Research, 60, 2680–2688.
   Google Scholar
• PASTORINO, U., ANDREOLA, S., TAGLIABUE, E., PEZZELLA, F., INCARBONE, M., SOZZI, G., BUYSE, M., MENARD, S., PIEROTTI, M. and RILKE, F., 1997, Immunocytochemical markers in stage I lung cancer: relevance to prognosis. Journal of Clinical Oncology, 15, 2858–2865.
   PubMed Web of Science ®Google Scholar
• REUTHER, G. W. and DER, C. J., 2000, The Ras branch of small GTPases: Ras family members don't fall far from the tree. Current Opinions in Cell Biology, 12, 157–165.
   PubMed Web of Science ®Google Scholar
• SEBTI, S. M. and HAMILTON, A. D., 2000, Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Oncogene, 9, 2767–2782.
   Google Scholar
• SKLAR, M. D., 1988, The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science, 239, 645–647.
   PubMed Web of Science ®Google Scholar
• VAUPEL, P., THEWS, 0. and HOECKEL, M., 2001, Treatment resistance of solid tumors: role of hypoxia and anemia. Medical Oncology, 18, 243–259.
   Google Scholar
• WILLUMSEN, B. M., CHRISTENSEN, A., HUBBERT, N. L., PAPAGEORGE, A. G. and Lowy, D. R., 1984a, The p21 ras C-terminus is required for transformation and membrane association. Nature, 310, 583–586.
   PubMed Web of Science ®Google Scholar
• WILLUMSEN, B. M., NORRIS, K., PAPAGEORGE, A. G., HUBBERT, N. L. and Lowy, D. R., 1984b, Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO Journal, 3, 2581–2585.
   PubMed Web of Science ®Google Scholar